Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT00337207
Phase
PHASE2
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
    Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progressive glioma.

Key Dates

First listed
Jun 15, 2006
Start date
Mar 31, 2006
Status verified
Jan 2020
Primary completion
Nov 30, 2008
Completion
May 31, 2009

Study Design

Enrollment
55 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Avastin

Primary Outcome Measure

Safety of Treatment [ Time Frame: From treatment initiation, throughout treatment and up to 30 days post-treatment, for up to 1 year. ]

Locations (2)

FacilityCityStateZIPSite coordinators
Hematology-Oncology Associates of IllinoisChicagoIllinois60611-2998-
Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicagoIllinois60611-3013-

Find similar trials in Chicago, IL

By research site
Hematology-Oncology Associates of Illinois· Chicago, ILRobert H. Lurie Comprehensive Cancer Center at Northwestern University· Chicago, IL

Related Studies